MedTrace Logo

BOTOX® for the Treatment of Platysma Prominence

NCT03915067 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 171

Last updated 2023-05-03

Study results available
· View outcomes & findings →

Summary

To assess the efficacy and safety of BOTOX® in adults with moderate to severe platysma prominence.

Conditions

  • Platysma Prominence

Interventions

DRUG

BOTOX® purified neurotoxin complex

BOTOX® superficial intramuscular injections.

DRUG

Placebo

Placebo injections.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • ALLERGAN INC. · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-23
Primary Completion
2020-04-16
Completion
2020-04-16
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03915067 on ClinicalTrials.gov